We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.82%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
+$313M
(+14%)
Cap. Flow
+$193M
Cap. Flow
% of AUM
7.73%
Top 10 Holdings %
Top 10 Hldgs %
67.82%
Holding
55
New
8
Increased
16
Reduced
5
Closed
6
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jade Biosciences
JBIO
|
+$60.3M |
| 2 |
Zai Lab
ZLAB
|
+$31.5M |
| 3 |
Aura Biosciences
AURA
|
+$29.8M |
| 4 |
Evolus
EOLS
|
+$24.9M |
| 5 |
Cytokinetics
CYTK
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$36M |
| 2 |
Soleno Therapeutics
SLNO
|
+$35.7M |
| 3 |
Merus
MRUS
|
+$15.7M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$7.81M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
+$7.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.84% |
| 2 | Miscellaneous | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
CG Oncology
CGON
$5.48B
| $20M | 0.8% |
770,000
| – | – |
2024 Q1
5 quarters
|
|
27
DELISTED
Akero Therapeutics
AKRO
| $19.6M | 0.78% |
+366,784
| New | +$16.7M |
2025 Q2
0 quarters
|
|
|
28
Cytokinetics
CYTK
$8.89B
| $18.3M | 0.73% |
+554,731
| New | +$19.3M |
2025 Q2
0 quarters
|
|
29
Lexeo Therapeutics
LXEO
$227M
| $17.8M | 0.71% |
4,424,725
+3,469,210
| +363% | +$11.4M |
2024 Q3
3 quarters
|
|
|
RNAM
30
DELISTED
Avidity Biosciences
RNAM
| $17.8M | 0.71% |
625,000
+100,000
| +19% | +$2.98M |
2025 Q1
1 quarter
|
|
|
31
Jade Biosciences
JBIO
$875M
| $17.7M | 0.71% |
+1,772,116
| New | +$60.3M |
2025 Q2
0 quarters
|
|
32
Palvella Therapeutics
PVLA
$1.83B
| $16.3M | 0.65% |
722,400
+32,388
| +5% | +$760K |
2024 Q3
3 quarters
|
|
33
Vaxcyte
PCVX
$10.3B
| $15.4M | 0.62% |
474,405
-65,000
| -12% | -$2.13M |
2022 Q1
13 quarters
|
|
34
Travere Therapeutics
TVTX
$4.98B
| $14.8M | 0.59% |
+1,002,092
| New | +$16.6M |
2025 Q2
0 quarters
|
|
35
Dyne Therapeutics
DYN
$2.86B
| $14.3M | 0.57% |
1,505,984
+62,643
| +4% | +$690K |
2025 Q1
1 quarter
|
|
36
Cogent Biosciences
COGT
$5.12B
| $12.5M | 0.5% |
1,734,601
+798,025
| +85% | +$4.42M |
2022 Q1
13 quarters
|
|
37
Immunocore
IMCR
$1.52B
| $12.1M | 0.48% |
384,782
+83,612
| +28% | +$2.6M |
2024 Q2
4 quarters
|
|
38
Oric Pharmaceuticals
ORIC
$1.32B
| $10.8M | 0.43% |
1,065,334
-344,859
| -24% | -$2.32M |
2023 Q2
8 quarters
|
|
39
Autolus Therapeutics
AUTL
$458M
| $10.5M | 0.42% |
4,623,324
| – | – |
2022 Q1
13 quarters
|
|
40
Valneva
VALN
$560M
| $8.24M | 0.33% |
+1,458,333
| New | +$9.25M |
2025 Q2
0 quarters
|
|
41
Crescent Biopharma
CBIO
$464M
| $7.32M | 0.29% |
+453,685
| New | +$9.6M |
2025 Q2
0 quarters
|
|
42
Design Therapeutics
DSGN
$656M
| $6.58M | 0.26% |
1,953,547
| – | – |
2024 Q2
4 quarters
|
|
43
Oruka Therapeutics
ORKA
$4.89B
| $6.54M | 0.26% |
583,327
| – | – |
2024 Q3
3 quarters
|
|
44
Silence Therapeutics
SLN
$581M
| $5.63M | 0.23% |
970,130
-178,461
| -16% | -$765K |
2022 Q1
13 quarters
|
|
45
Allogene Therapeutics
ALLO
$463M
| $4.37M | 0.17% |
3,868,750
| – | – |
2024 Q1
5 quarters
|
|
46
NewAmsterdam Pharma Warrant
NAMSW
| $4M | 0.16% |
500,333
| – | – |
2022 Q4
10 quarters
|
|
47
MacroGenics
MGNX
$215M
| $3.84M | 0.15% |
3,175,665
| – | – |
2023 Q1
9 quarters
|
|
48
DELISTED
Adverum Biotechnologies
ADVM
| $2.3M | 0.09% |
1,069,244
| – | – |
2024 Q1
5 quarters
|
|
49
DELISTED
Elevation Oncology
ELEV
| $2.2M | 0.09% |
5,993,579
| – | – |
2024 Q2
4 quarters
|
|
|
50
Acadia Pharmaceuticals
ACAD
$3.4B
| – | – |
-470,338
| Closed | -$7.81M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q2 2025 Portfolio in Review
As of Q2 2025, Frazier Life Sciences Management held 55 positions worth $2.5B, up 14% from $2.19B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Frazier Life Sciences Management deployed $193M of net new capital in Q2 2025, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was Jade Biosciences: 1,772,116 shares worth $17.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Verona Pharma, an estimated $5.47M trimmed.
- Frazier Life Sciences Management's largest Q2 2025 buy was Jade Biosciences: 1,772,116 shares worth $17.7M.
- Frazier Life Sciences Management added most to Zai Lab in Q2 2025, an estimated $31.5M increase.
- Frazier Life Sciences Management's biggest Q2 2025 reduction was Verona Pharma, cutting an estimated $5.47M.
- Frazier Life Sciences Management fully exited Rhythm Pharmaceuticals in Q2 2025, selling an estimated $36M.
- Frazier Life Sciences Management's ten largest holdings make up 68% of its $2.5B portfolio in Q2 2025.
- Frazier Life Sciences Management opened 8 new positions and closed 6 in Q2 2025.
- Frazier Life Sciences Management's portfolio value rose 14% quarter-over-quarter to $2.5B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2025, filed 14 Aug 2025.